Comparing 18F-AV133 VMAT2 PET and DATscan as Markers of Parkinson’s Disease Severity and Progression
Objective: Compare VMAT2 PET signal with DATscan at baseline and over time, and evaluate their correlations with MDS-UPDRS III. Background: DATscan is a Parkinson’s disease…Evaluating the association between cognitive impairment and striatal VMAT2 binding using [18F]AV-133 PET in Parkinson’s disease
Objective: To evaluate the association between cognitive deficits and striatal vesicular monoamine transporter type 2 (VMAT2) binding in participants with Parkinson’s disease (PD) using [18F]AV-133…The effect of APOE ε4 on striatal vesicular monoamine transporter-2 density in Parkinson’s disease
Objective: To evaluate the effect of apolipoprotein E 4 (APOE 4) on striatal vesicular monoamine transporter-2 (VMAT2) density in Parkinson’s disease (PD).To evaluate the effect…Trajectories of Tardive Dyskinesia Impact Scale (TDIS) and Abnormal Involuntary Movement Scale (AIMS) over time with valbenazine treatment
Objective: To assess TDIS and global AIMS measures change trajectories using data from KINECT-4, an open-label 52-week trial assessing valbenazine in TD [1] Background: AIMS…Automated VMAT2 [18F]AV-133 PET analysis in Parkinson’s disease
Objective: To evaluate a fully automated image analysis pipeline to process vesicular monoamine transporters type 2 (VMAT2) [18F]AV-133 tracer positron emission tomography (PET) images, by…Real-world effectiveness and safety of deutetrabenazine in patients with chorea associated with Huntington disease
Objective: To assess real-world effectiveness and safety of deutetrabenazine (DTBZ) for chorea associated with Huntington disease (HD). Background: Real-world evidence on the impact of DTBZ…Efficacy and safety of deutetrabenazine in children and adolescents with dyskinesia in cerebral palsy
Objective: To evaluate the efficacy and safety of deutetrabenazine (DTBZ) in children and adolescents with dyskinesia in cerebral palsy (DCP). Background: There are currently no…A minimal clinically important difference for UHDRS® Total Maximal Chorea score as a measure of chorea severity in Huntington disease
Objective: To establish a minimal clinically important difference (MCID) for the Unified Huntington Disease Rating Scale (UHDRS®) Total Maximal Chorea (TMC) score as a measure…Long-term Deutetrabenazine Safety on Motor, Psychiatric, and Cognitive Measures in Individuals With Chorea Associated With Huntington Disease
Objective: To evaluate long-term deutetrabenazine safety on motor, psychiatric, and cognitive measures in participants with chorea associated with Huntington disease (HD). Background: Deutetrabenazine, a vesicular…Baseline Characteristics and Treatment Patterns of a Global Huntington Disease Population Stratified by Chorea Severity
Objective: To describe baseline characteristics and treatment patterns in patients with chorea associated with Huntington disease (HD) by severity of chorea. Background: Though multiple treatment…
- 1
- 2
- 3
- …
- 5
- Next Page »